by dyadic | Jun 15, 2026 | Press Releases
Company’s C1 platform may help address urgent need for rapid, scalable vaccine and antibody manufacturing while supporting broader commercialization across life sciences, food, nutrition and industrial marketsJUPITER, Fla., June 15, 2026 (GLOBE NEWSWIRE) —...
by dyadic | May 28, 2026 | Press Releases
Collaboration Leverages Prior Andes, Marburg and Ebola Virus Research and Dyadic’s C1 Platform Capabilities for Fast, Scalable Biologic ProductionJUPITER, Fla., May 28, 2026 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic,”...
by dyadic | May 21, 2026 | Press Releases
JUPITER, Fla., May 21, 2026 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), d/b/a Dyadic Applied BioSolutions, a global biotechnology...
by dyadic | May 19, 2026 | Press Releases
JUPITER, Fla., May 19, 2026 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic,” “we,” “us,” “our,” or the “Company”) (NASDAQ: DYAI), d/b/a Dyadic Applied BioSolutions, a global biotechnology...
by dyadic | May 13, 2026 | Press Releases
Received initial purchase orders for recombinant bovine transferrin from customers in the cultivated meat industryCommercial launch of AlbuFree™ DX recombinant human albumin by Proliant Health & Biologicals using Dyadic’s production platform, with...
by dyadic | Apr 29, 2026 | Press Releases
JUPITER, Fla., April 29, 2026 (GLOBE NEWSWIRE) — Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI), a global biotechnology...
